A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab

OncoImmunology

Volumn 4, Issue 11, 2015, Pages

  Chandra, Ravi A ^a   Wilhite, Tyler J ^b   Balboni, Tracy A ^c   Alexander, Brian M ^c   Spektor, Alexander ^c   Ott, Patrick A ^d   Ng, Andrea K ^c   Hodi, F Stephen ^d   Schoenfeld, Jonathan D ^c  

^a HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

abscopal effect; immunotherapy; ipilimumab; melanoma; radiation therapy

Indexed keywords

IPILIMUMAB;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; MALE; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PALLIATIVE THERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; STEREOTACTIC RADIOSURGERY; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 84941784779     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1046028     Document Type: Article

References (26)

1. R.Siegel, M.Jiemin, Z.Zhaohui, A.Jemal. Cancer statistics, 2014. CA Cancer J Clin 2013; 64:9-29; PMID:24399786; http://dx.doi.org/10.3322/caac.21208
2. A.M.M.Eggermont C.Robert. New drugs in melanoma: it's a whole new world. Eur J Cancer 2011; 47:2150-7; PMID:21802280; http://dx.doi.org/10.1016/j.ejca.2011.06.052
3. F.S.Hodi, S.J.O'Day, D.F.McDermott, R.W.Weber, J.A.Sosman, J.B.Haanen, R.Gonzalez, C.Robert, D.Schadendorf, J.C.Hassel et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
4. C.Robert, L.Thomas, I.Bondarenko, S.O'Day, J.Weber, C.Garbe, C.Lebbe, J.F.Baurain, A.Testori, J.J.Grob et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
5. C.M.Balch, A.C.Buzaid, S.J.Soong et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-48; PMID:1150475
6. J.P.S.Knisely, J.B.Yu, J.Flanigan M.Sznol, H.M.Kluger, V.L.Chiang. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 2012; 117:227-33; PMID:22702482; http://dx.doi.org/10.3171/2012.5.JNS111929
7. M.A.Postow, M.K.Callahan, C.A.Barker, Y.Yamada, J.Yuan, S.Kitano, Z.Mu, T.Rasalan, M.Adamow, E.Ritter et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366:925-31; PMID:22397654; http://dx.doi.org/10.1056/NEJMoa1112824
8. E.F.Stamell, J.D.Wolchok, S.Gnjatic N.Y.Lee, I.Brownell. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys 2013; 85:293-5; PMID:22560555; http://dx.doi.org/10.1016/j.ijrobp.2012.03.017
9. S.Demaria, B.Ng, M.L.Devitt J.S.Babb, N.Kawashima, L.Liebes, S.C.Formenti. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune-mediated. Int J Radiat Oncol Biol Phys 2004; 58:862-70; PMID:14967443; http://dx.doi.org/10.1016/j.ijrobp.2003.09.012
10. S.Demaria, N.Kawashima, A.M.Yang M.L.Devitt, J.S.Babb, J.P.Allison, S.C.Formenti. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005; 11:728-34; PMID:15701862
11. M.Z.Dewan, A.E.Galloway, N.Kawashima J.K.Dewyngaert, J.S.Babb, S.C.Formenti, S.Demaria. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009; 15:5379-88; PMID:19706802; http://dx.doi.org/10.1158/1078-0432.CCR-09-0265
12. A.M.Grimaldi, E.Simeone, D.Giannarelli, P.Muto, S.Falivene, V.Borzillo, F.M.Giugliano, F.Sandomenico, A.Petrillo, M.Curvietto et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology 2014; 3:e28780; PMID:25083318; http://dx.doi.org/10.4161/onci.28780
13. R.H.Mole. Whole body irradiation: radiobiology or medicine? Br J Radiol 1953; 26:234-41; PMID:13042090; http://dx.doi.org/10.1259/0007-1285-26-305-234
14. D.Schadendorf, F.S.Hodi, C.Robert, J.S.Weber, K.Margolin, O.Hamid, D.Patt, T.T.Chen, D.M.Berman, J.D.Wolchok. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015 Jun 10; 33(17):1889-94. doi: 10.1200/JCO.2014.56.2736. Epub 2015 Feb 9. PMID: 25667295
15. C.Drake: Radiation-induced immune modulation, in T.L.DeWeese, M.Laiho (eds.): Molecular determinants of radiation response. New York, NY, Springer, 2011, 251-63; http://dx.doi.ogr/1007/978-1-4419-8044-1.
16. S.Matsumura, B.Wang, N.Kawashima, S.Braunstein, M.Badura, T.O.Cameron, J.S.Babb, R.J.Schneider, S.C.Formenti, M.L.Dustin et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 2008; 181:3099-107; PMID:18713980; http://dx.doi.org/10.4049/jimmunol.181.5.3099
17. E.Reits, J.Hodge, C.A.Herberts, T.A.Groothuis, M.Chakraborty, E.K.Wansley, K.Camphausen, R.M.Luiten, A.H.de Ru, J.Neijssen et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunity. J Exp Med 2006; 203:1259-71; PMID:16636135; http://dx.doi.org/10.1084/jem.20052494
18. S.C.Formenti, S.Demaria. Combining radiotherapy and cancer immunotherapy: A paradigm shift. J Natl Cancer Inst 2013; 105:256-65; PMID:23291374; http://dx.doi.org/10.1093/jnci/djs629
19. A.Levy, C.Chargari, M.Cheminant, N.Simon, C.Bourgier, E.Deutsch. Radiation therapy and immunotherapy: Implications for a combined cancer treatment. Crit Rev Oncol Hematol 2012; 85:278-87; PMID:23036459; http://dx.doi.org/10.1016/j.critrevonc.2012.09.001
20. H.E.Teulings, E.P.M.Tjin, K.J.Willemsen. Radiation induced melanoma-associated-leukoderma, systemic anti-melanoma immunity and disease-free survival in an advanced stage melanoma patient: A case report and immunological analysis. Br J Dermatol 2013; 168:733-8; PMID:23421690; http://dx.doi.org/10.1111/bjd.12136
21. + T cells: Changing strategies for cancer treatment. Blood 2009; 114:589-95; PMID:19349616; http://dx.doi.org/10.1182/blood-2009-02-206870
22. J.P.Williams, S.L.Brown, G.E.Georges, M.Hauer-Jensen, R.P.Hill, A.K.Huser, D.G.Kirsch, T.J.Macvittie, K.A.Mason, M.M.Medhora et al. Animal models for medical countermeasures to radiation exposure. Radiat Res 2010; 173:557-78; PMID:20334528; http://dx.doi.org/10.1667/RR1880.1
23. + T cell functionality and mucosal homing. Virology 2007; 367:156-67; PMID:17590405; http://dx.doi.org/10.1016/j.virol.2007.05.028
24. E.B.Golden, S.Demaria, P.B.Schiff A.Chachoua, S.C.Formenti. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 2013; 1:365-72; PMID:24563870; http://dx.doi.org/10.1158/2326-6066.CIR-13-0115
25. E.Kwon, C.Drake, H.Scher, K.Fizazi, A.Bossi, A.J.van den Eertwegh, M.Krainer, N.Houede, R.Santos, H.Mahammedi et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014; 15:700-12; PMID:24831977; http://dx.doi.org/10.1016/S1470-2045(14)70189-5
26. J.D.Wolchok, A.Hoos, S.O'Day, J.S.Weber, O.Hamid, C.Lebbé, M.Maio, M.Binder, O.Bohnsack, G.Nichol et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 2009; 15:7412-20; PMID:19934295; http://dx.doi.org/10.1158/1078-0432.CCR-09-1624